| Literature DB >> 23936333 |
Sabrina H van Ierssel1, Emeline M Van Craenenbroeck, Vicky Y Hoymans, Christiaan J Vrints, Viviane M Conraads, Philippe G Jorens.
Abstract
BACKGROUND: Outcome in sepsis is mainly defined by the degree of organ failure, for which endothelial dysfunction at the macro- and microvascular level is an important determinant. In this study we evaluated endothelial function in patients with severe sepsis using cellular endothelial markers and in vivo assessment of reactive hyperaemia.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23936333 PMCID: PMC3735536 DOI: 10.1371/journal.pone.0069499
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Patient screening.
From May 2010 until January 2012, we screened 159 patients with severe sepsis for this study. The major exclusion reason (n = 41) was a diagnosis longer than 72 h before inclusion. This is due to the fact that our center is a tertiary care hospital accepting referrals from ICU's from surrounding centers. In 27 (*) patients there were arguments for cardiogenic or hypovolemic shock or an ischemic event at the time of diagnosis. Four patients had a DNR code at screening, in another 17 consent was refused, 4 died before analysis could be performed, 16 had a recurrent sepsis or a longer standing infection with antibiotic use before diagnosis. Twenty patients could not be analyzed due to technical problems (instrument malfunctioning, unavailability of the instruments).
Figure 2Outline of the study.
Flow chart representing the timeline used for measurements and assessment of disease severity.CAC = circulating angiogenic cell, EMP = endothelial microparticle, EPC = endothelial progenitor cell, RHI = reactive hyperaemia, SAPS = Simplified Acute Physiology; SOFA = Sequential of Organ Failure Assessment.
Baseline characteristics of the severe sepsis patients (n = 30).
| Age (years) | 63.0±2.9 | Infection | |
| BMI | 26.2±0.9 | - Pneumonia | 11 (37%) |
| Male | 20 (67%) | - Intra-abdominal | 8 (27%) |
| Co-morbidity | - Skin and soft tissue | 4 (13%) | |
| - Obesity | 5 (17%) | - Urosepsis | 2 (7%) |
| - Cardiovascular disease | 12 (40%) | - Other | 5 (17%) |
| - Hyperlipidaemia | 5 (17%) | Bacteraemia | 9 (30%) |
| - Diabetes | 5 (17%) | Microbiological confirmation | 25 (83%) |
| - Malignancy | 6 (20%) | Treatment | |
| - Chronic kidney disease | 2 (7%) | Adequate antibiotics (n = 25) | 19 (76%) |
| - Inflammatory disease | 2 (7%) | - Surgery | 16 (53%) |
| - Immunosuppressed | 6 (20%) | - Mechanical ventilation | 17 (57%) |
| Chronic medication | - Renal replacement therapy | 5 (17%) | |
| - ACE-inhibitor or sartan | 7 (23%) | - Corticosteroids | 8 (27%) |
| - Statins | 5 (17%) | - Immunoglobulins | 3 (10%) |
| - Corticosteroids | 4 (13%) | Vasopressors/Inotropics number (mean max dose ± SEM) | |
| Sepsis Severity | - Norepinephrine (μg/kg/min) | 21 (0.35±0.04) | |
| - SAPSIII | 61.7±1.9 | - Adrenaline (μg/kg/min) | 2 (0.16±0.12) |
| - SOFA D0 | 7.8±0.6 | - Dobutamine (μg/kg/min) | 5 (4.5±0.7) |
| Clinical parameters | - Vasopressin (IE/h) | 6 (2.3±0.6) | |
| - MAP (mmHg) | 79.2±1.6 | - Milrinone (μg/kg/min) | 2 (0.21±0.04) |
| - MII | 23.3±8.5 | ICU stay (h) | 286±69 |
| - VDI | 8.1±1.8 | Hospital stay (d) | 41±8 |
| Hospital mortality (n = 28) | 4 (14%) |
BMI = body mass index; ICU = intensive care unit; MAP = Mean arterial pressure; MII = Modified Inotropic Index; POD = persistent organ failure; SAPS = Simplified Acute Physiology; SOFA = Sequential of Organ Failure Assessment; VDI = Vasopressor Dependency Index; h = hour; d = day.
Data presented as mean ± SEM or as number (percentage).
Comparison of markers of endothelial function in severe sepsis with those in healthy volunteers.
| Variable (n | Severe Sepsis | Healthy volunteers | p-value |
| Age in years (30,15) | 63.0±2.9 | 56.5±3.5 | 0.187 |
| BMI (30,15) | 26.2±0.9 | 24.0±0.7 | 0.105 |
| Male (30,15) | 20 (67%) | 8 (53%) | 0.384 |
| WBC x106/ml (30,15) | 14.9±1.4 | 5.3±0.3 | <0.001 |
| PBMC x106/ml (28,15) | 1.3±0.2 | 2.0±0.1 | <0.001 |
| CD34+ cells/ml (28,15) | 2225±532 | 2461±435 | 0.019 |
| CD34/105PBMC (30,15) | 190.1±39.5 | 131.5±26.3 | 0.942 |
| EPC/ml (28,15) | 213.1±45.1 | 452.0±107.2 | 0.001 |
| EPC/105 PBMC (30,15) | 22.6±3.9 | 24.1±6.3 | 0.273 |
| %CD31+ T-cells (30,15) | 35.1±2.5 | 43.1±2.6 | 0.050 |
| %CD184+CD31+ T-cells (30,15) | 91.8±1.1 | 83.0±1.8 | <0.001 |
| EMP/μl (26,15) | 203.3±20.3 | 205.2±23.5 | 0.739 |
| %CAC migration (17,14) | 32.5±3.5 | 45.3±4.9 | 0.038 |
| RHI (20,15) | 1.88±0.11 | 2.41±0.14 | 0.004 |
BMI = body mass index; CAC = circulating angiogenic cell, EPC = endothelial progenitor cell; EMP = endothelial microparticle; PBMC = peripheral blood mononuclear cells; RHI = reactive hyperaemia index, WBC = White blood cell count.
Data presented as mea n± SEM or as number (percentage).
n = indicates number of patients with severe sepsis and healthy volunteers analysed.
Comparison of markers of endothelial function between patients with and those without progression of organ failure in the first week.
| Variable (n | Progression of organ failure | No progression of organ failure | p-value |
| SAPS III (12, 18) | 66.3±3.1 | 58.1±1.7 |
|
| SOFA (12, 18) |
|
| 0.298 |
| PBMC x106/ml (11,17) | 0.9±0.2 |
|
|
| CD34+ cells/ml (11,17) |
|
|
|
| CD34/105PBMC (12, 18) |
|
| 0.691 |
| EPC/ml (11,17) |
|
|
|
| EPC/105 PBMC (12, 18) | 23.2±8.0 |
|
|
| %CD31+ T-cells (12, 18) |
| 37.8±3.3 |
|
| %CD184+CD31+ T-cells (12, 18) | 94.6±1.3 |
|
|
| EMP/μl (10,16) |
|
|
|
| %CAC migration (6,11) |
|
|
|
| RHI (7,13) |
|
|
|
CAC = circulating angiogenic cell, EPC = endothelial progenitor cell; EMP = endothelial microparticle; PBMC = peripheral blood mononuclear cells; RHI = reactive hyperaemia index, SAPS = Simplified Acute Physiology; SOFA = Sequential of Organ Failure Assessment.
Data presented as mean ± SEM or as number (percentage).
n = number of patients analysed with progression and no progression of organ failure respectively.